Millendo has received series B funding from investors including Roche, while AstraZeneca acquired a stake in the biopharmaceutical company through a licensing deal.
US-based biopharmaceutical company Millendo Therapeutics raised $62m in series B funding yesterday from a consortium of investors including Roche Venture Fund, the corporate venturing division of healthcare company Roche.
Venture capital firm New Enterprise Associates (NEA) led the round, which followed a $16m series A round in 2012 co-led by Frazier Healthcare Partners and 5AM Ventures.
The series B round also included Frazier, 5AM, the regents of University of Michigan under the Michigan Investment in New Technology Startup program, Osage…
